mRNA Vaccines and Therapeutics Market (By Disease Type: Hereditary Transthyretin-mediated Amyloidosis Genetic, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Atherosclerotic Cardiovascular Disease; By Route of Administration: IV Infusion, Subcutaneous; By End-user Type: Research Institutes, Hospitals and Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: MRNA Vaccines and Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by Disease Type, 2024-2033
8.1.1 Hereditary Transthyretin-mediated Amyloidosis Genetic
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Acute Hepatic Porphyria
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Primary Hyperoxaluria Type 1
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Atherosclerotic Cardiovascular Disease
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by Route of Administration, 2024-2033
9.1.1. IV Infusion
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by End-user Type, 2024-2033
10.1.1. Research Institutes
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Hospitals and Clinics
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)
12.1. Kernal Biologics Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Argos Therapeutics Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Charoen Pokphand Group
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AIM Vaccine Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CureVac SE
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Ethris GmbH
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bohringer Ingelheim International GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Arcturus
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Daiichi Sankyo
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample